Phase 3 Data on solanezumab for Preclinical Alzheimer's.

Published Date: 22 Jul 2023

According to the findings of a phase 3 trial, solanezumab, a monoclonal antibody that binds to the soluble or monomeric form of amyloid-beta, is not any more effective than a placebo at slowing the progression of preclinical Alzheimer's.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

PET-CT finds further-reaching metastases in patients with locally advanced breast cancer.

2.

Reasons Behind Refusing Stem Cell Transplantation in Certain Myeloma Patients.

3.

Hospitalization and mortality rates are associated with exposure to the omicron variant of COVID-19 in patients with solid cancer.

4.

AI System Beats Radiologists in Detecting Clinically Significant Prostate Cancer

5.

In heavily pretreated DLBCL, Triplet Scores a Survival Victory.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot